| Patent application number | Description | Published |
|---|
| 20080267908 | Il-32 Modulators - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. Proteinase 3 has been identified as an IL-32 binding protein capable of deavege thereof. Inhibition of PR 3 activity to process IL-32 or neutralization of IL-32 by-inactive PR3 or its fragments may reduce the consequences of IL-32 in immune regulated diseases (e.g. inflammatory diseases). | 10-30-2008 |
| 20090074710 | METHOD OF TREATMENT USING A CYTOKINE ABLE TO BIND IL-18BP TO INHIBIT THE ACTIVITY OF A SECOND CYTOKINE - The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof capable of binding to IL-18BP or a mutein, fused protein, functional derivative or fragment thereof and capable of inhibiting a receptor of a cytokine-2, cytokine-2 being a member of the IL-1 family, preferably IL-18, in the manufacture of a medicament for the treatment or prevention of a disease which is caused or aggravated by inducing said receptor of cytokine-2. | 03-19-2009 |
| 20090093434 | USE OF EIF-5A1 SIRNA TO PROTECT ISLETS CELLS FROM APOPTOSIS AND TO PRESERVE THEIR FUNCTIONALITY - The present invention relates to methods for improving the viability, recovery and functionality of islets that are separated from a donor organ for subsequent transplantation and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability and functionality of islets. | 04-09-2009 |
| 20090118162 | INHIBITORS OF SERINE PROTEASE ACTIVITY AND THEIR USE IN METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities. | 05-07-2009 |
| 20090203580 | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity - Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating graft rejection, transplant rejection or diabetes in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin, wherein the alpha-1 antitrypsin has no significant serine protease inhibitor activity. | 08-13-2009 |
| 20090220518 | METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL - Embodiments herein illustrate methods of treating, reducing or preventing transplantation rejection and/or side effects associated with transplantation. Some embodiments relate to compositions and methods for inhibition of graft rejection and promotion of graft survival. Other embodiments relate to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. Yet other embodiments relate to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease, derivatives and fragments of the carboxy-terminus of alpha1-antitrypsin and inducers of other alpha1-antitrypsin activities and uses thereof. | 09-03-2009 |
| 20090286855 | INTERLEUKIN-18 MUTANTS, THEIR PRODUCTION AND USE - The invention provides mutants of IL-18 with lower affinity to IL-18BP than the wild type IL-18 molecule. | 11-19-2009 |
| 20110044999 | IL-32 MODULATORS - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. | 02-24-2011 |
| 20110112017 | COMPOSITIONS, METHODS AND USES FOR TREATING DIABETES - Embodiments herein concern compositions and methods for treating diabetes in a subject. | 05-12-2011 |
